regeneron pharmaceuticals semaglutide announced on January 30, 2026, that its experimental obesity drug candidate delivers significant SkinnyRx: Injectable Semaglutide (GLP-1)

GLP-1 medications may cause rapid weight loss, which can result in a hollowed look to the face, sunken eyes, wrinkles, sagging skin and changes in the size of your lips, cheeks and chin

Hypothyroid patients may have an increased risk for digitalis toxicity

How do I feel on this medication

The most common side effects were gastrointestinal, the company added, with the vast majority being mild to moderate in severity

Begin your journey with a personalized online consultation with an experienced provider, during which a tailored treatment plan is developed

This perspective promotes the development of integrative medicine models, emphasizing the intrinsic connection between somatic and psychiatric symptoms and suggesting the need for multidisciplinary collaboration between gastroenterology and psychiatry